Stock Analysis

On 2 September 2026 the company announced that the Phase 2a study of PTX-100 in relapsed or refractory cutaneous T-cell lymphoma (CTCL) had reached its pre-specified enrolment threshold for the first planned Dose Optimisation Committee (DOC) review. Ten evaluable patients have been enrolled in …

The OLE enables patients who complete Part C of the Phase 1b trial to receive PYC-003 continuously for up to 24 months, mirroring the duration of the registrational trial planned after the Phase 1b study. The first enrolled patient has finished dosing in the …

The SRC reviewed all safety data from both Cohort 1 patients, who received RC220 at 50 mg/m2 with osimertinib at 80 mg daily. No dose-limiting toxicities or treatment-related safety concerns were identified in either patient during the safety observation period. The second patient had …

The baseline interest-only period has been extended by three months to 31 December 2026. The agreement adds two subsequent interest-only extension options, which could take the period through to 30 September 2027. Those extensions are contingent on Recce meeting defined capital raising targets and …

Argent says proceeds will be used for working capital, covering corporate costs andResearch and Developmentactivities. The announcement does not describe any specific project or milestone funded by the loans.

The study modelled about 83,000 people a year who see a GP with possible bowel cancer symptoms, have not done the national stool test and would currently be referred directly to a public hospital for a colonoscopy. It compared that pathway with a GP …

The pre-submission meeting, supported by written feedback, gave ReNerve the chance to discuss its regulatory plan for the NGM with the FDA before making a formal submission. The company says the discussions confirmed its submission strategy while also providing feedback from the regulator. The …